Early Phase Study Aims to Improve OS in HER2+ Breast Leptomeningeal Disease

Kamran A. Ahmed, MD, gives an overview of the phase 1/2 study of radiation therapy followed by intrathecal trastuzumab and pertuzumab in the management of HER2-positive breast leptomeningeal disease.

Kamran A. Ahmed, MD, a radiation oncologist at the Moffitt Cancer Center, gives an overview of the phase 1/2 study of radiation therapy followed by intrathecal trastuzumab (Herceptin) and pertuzumab (Perjeta) in the management of HER2-positive breast leptomeningeal disease.

According to Ahmed, patients with HER2-positive leptomeningeal disease have a poor prognosis and high unmet clinical need. On its own, radiotherapy remains an important treatment strategy for leptomeningeal disease and trastuzumab is an important treatment for HER2-positive breast cancer. According to Ahmed, there is a strong clinical rationale for their combination for the treatment of HER2-positive breast leptomeningeal disease.

The phase 1/2 study has a single arm. After treatment is initiated, patients will receive either 10mg, 20mg, 40mg, or 80mg of pertuzumab. The trastuzumab dose will remain stable. In order to participate, patients must have a life expectancy of at least 8 weeks.